12.23  -0.11 (-0.89%)		04-25 16:00
Open: 12.34 High: 12.37 Volume: 1,152,108		Pre. Close: 12.34 Low: 11.88 Market Cap: 1,316(M)

Short term
Mid term
Targets	6-month :	16.8	1-year :	18.74
Resists	First :	14.38	Second :	16.04
Pivot price	12.99
Supports	First :	11.69	Second :	9.73
MAs	MA(5) :	12.1	MA(20) :	13.45
	MA(100) :	14.18	MA(250) :	26.08
MACD	MACD :	-0.7	Signal :	-0.6
%K %D	K(14,3) :	13.5	D(3) :	9.8
RSI	RSI(14): 38.1
52-week	High :	83.59	Low :	10.86

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NVCR ] has closed above bottom band by 31.4%. Bollinger Bands are 39.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	12.38 - 12.45	12.45 - 12.51
Low:	11.73 - 11.8	11.8 - 11.86
Close:	12.11 - 12.23	12.23 - 12.34

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.

Thu, 25 Apr 2024
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

Thu, 25 Apr 2024
NovoCure (NASDAQ:NVCR) Share Price Passes Below 50 Day Moving Average of $14.57 - MarketBeat

Thu, 25 Apr 2024
NovoCure (NVCR) to Release Earnings on Thursday - MarketBeat

Thu, 25 Apr 2024
Federated Hermes Inc. Has $9.21 Million Position in NovoCure Limited (NASDAQ:NVCR) - MarketBeat

Thu, 25 Apr 2024
NVCR (NovoCure) Free Cash Flow - GuruFocus.com

Mon, 08 Apr 2024
NovoCure (NASDAQ:NVCR) Has Debt But No Earnings; Should You Worry? - Simply Wall St

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Shares Out	107 (M)
Shares Float	98 (M)
Held by Insiders	1.6 (%)
Held by Institutions	85.7 (%)
Shares Short	5,010 (K)
Shares Short P.Month	5,640 (K)

EPS	-1.96
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.38
Profit Margin	-40.7 %
Operating Margin	-33.7 %
Return on Assets (ttm)	-12.1 %
Return on Equity (ttm)	-51.6 %
Qtrly Rev. Growth	4.1 %
Gross Profit (p.s.)	0
Sales Per Share	4.75
EBITDA (p.s.)	-2.03
Qtrly Earnings Growth	0 %
Operating Cash Flow	-73 (M)
Levered Free Cash Flow	-10 (M)

PE Ratio	-6.28
PEG Ratio	-0.2
Price to Book value	3.61
Price to Sales	2.57
Price to Cash Flow	-17.86

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.